6505--FY27 Low Energy General Radiopharmaceuticals 36C25027Q0052
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
250-NETWORK CONTRACT OFFICE 10 (36C250)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36C25027Q0052
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents2
The Department of Veterans Affairs (VA), through its Network Contract Office 10, is conducting market research to identify qualified sources capable of providing low energy general radiopharmaceuticals (excluding FDG F-18 agents) in unit-dose, patient-specific form. This requirement supports the diagnostic and limited therapeutic nuclear medicine needs of the VA Northeast Ohio Healthcare System in Cleveland, OH, and the VA Kent Imaging and Infusion Center in Kent, OH. The anticipated contract period is a one-year base (January 1, 2027, to December 31, 2027) with four additional 12-month option years, potentially extending through December 31, 2031.
The primary objective of this procurement is to ensure the reliable supply of a comprehensive range of low energy radiopharmaceuticals for both routine and emergent clinical use. The products will be used in various nuclear medicine imaging and therapeutic procedures, with annual estimated quantities provided for each required agent. The scope encompasses the compounding, calibration, labeling, and timely delivery of these radiopharmaceuticals, with strict adherence to regulatory and industry standards.
Key requirements include:
- Compounding and calibration of all doses by or under the supervision of a certified Nuclear Pharmacist, in compliance with USP and USP standards, as well as all applicable Board of Pharmacy, FDA, NRC, CDC, and Joint Commission regulations.
- The ability to fulfill both routine and emergent orders, with emergent deliveries required within 120 minutes of order receipt (via phone, fax, or electronic means) to either the Cleveland or Kent locations, including outside regular business hours.
- Prompt processing and delivery of specialized products such as Tc-99m tagged white blood cell (WBC) orders.
- Accurate labeling of all products, including radiopharmaceutical identity, activity, concentration, preparation and calibration times, total volume, expiration details, and bar-code labeling for integration with the Nuclear Medicine Information System (NMIS). All syringes, vials, and associated shields must be properly labeled.
The estimated annual requirements cover a wide array of radiopharmaceuticals, including but not limited to: 99mTc Sulfur Colloid, 99mTc MDP, 99mTc Mebrofenin, 99mTc MAG-3, 99mTc Tetrofosmin, 99mTc MAA, 111In Pentreotide, 99mTc Sestamibi, 99mTc and 111In WBC labeling kits, I-123 and I-131 iodine capsules, UltraTag kits, 123I MIBG, 67Ga Gallium Citrate, and others. Quantities range from high-volume items such as 99mTc Sestamibi (5,000 doses annually) to low-volume, specialized agents.
Interested vendors must already possess all necessary licenses, registrations, and authorizations to receive, possess, compound, prepare, transport, distribute, and dispose of radioactive byproduct materials and radiopharmaceutical isotopes. At a minimum, this includes a current, unrevoked Nuclear Regulatory Commission (NRC) and/or applicable Agreement State license for the production and distribution of radiopharmaceuticals for human use, as well as all relevant FDA, DOT, and state/local authorizations. Respondents must affirmatively confirm their licensure status and be regularly established in the business of providing radionuclides.
This notice is classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), with a small business size standard of 1,300 employees, and Product Service Code 6505 (Drugs and Biologicals). The place of performance is specified as Hot Lab Room B-C432 at 10701 East Blvd., Cleveland, OH 44106, and Hot Lab Room B109 at 3838 Cascades Blvd., Kent, OH 44240.
The VA is particularly interested in responses from Service-Disabled Veteran-Owned Small Businesses (SDVOSBs), Veteran-Owned Small Businesses (VOSBs), and other small business concerns, as this information will inform the acquisition strategy and potential set-aside determinations under the Veterans First Contracting Program (VAAR 819.70) and the Rule of Two. The Nonmanufacturer Rule and Limitations on Subcontracting will apply to any resulting SDVOSB/VOSB set-aside or sole-source award above the micro-purchase threshold.
Respondents are required to provide:
- Manufacturer authorization documentation for the radiopharmaceuticals offered.
- Identification of the manufacturer(s) for each product.
- Business size and socioeconomic status under NAICS 325412.
- Confirmation of the ability to supply all required items, or a detailed list of any exceptions.
- Information on GSA, NAC, or SAC contract availability, with contract numbers if applicable.
- SAM Unique Entity Identifier (UEI) and confirmation of active SAM.gov registration.
- Affirmative statements regarding current licensure and delivery capabilities, including the ability to meet all SOW requirements and emergent delivery timelines.
- (Optional) Company contact information, a brief capability statement, and relevant prior experience.
Responses are due electronically by 9:00 AM Eastern Time on Tuesday, November 3, 2026, to [email protected], referencing Sources Sought Notice 36C25027Q0052. Questions should be directed to the same contact prior to the response deadline. No phone calls are accepted.
This is a Sources Sought Notice for market research purposes only and does not constitute a solicitation or a commitment by the Government to award a contract. All prospective offerors must be registered in SAM.gov to be eligible for any future solicitation. The Buy American Act and Trade Agreements Act provisions will apply to any resulting procurement.
For further details and to access attachments, interested parties should refer to the official posting on SAM.gov (Opportunity ID: 15fafc99ab5b43e4afc21e7f8067d07b).